
Founded in 2007, Genor Biopharma Co. Ltd (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's top oncology areas (breast, lung, and gastrointestinal cancer).
Genor Biopharma is creating a fully integrated and end-to-end biopharma innovation company based in China, with global reach. In San Francisco, the cutting-edge bispecific and multi-specific discovery platform (Antibody Therapeutics Inc.) engineers novel and highly differentiated therapeutic antibody candidates with display technology, computer-aided design, and site mutagenesis. The industry leading R&D center located in Shanghai focuses on CMC (Chemistry, Manufacturing, and Controls) development. This center is capable of developing comprehensive bioprocesses and formulations, and manufacturing preclinical and clinical materials with advanced analytical, quality control, and quality assurance systems for compliance. In 2016, the GMP commercial manufacturing facility was built and commissioned in Yuxi, Yunan and is currently operating with a highly GMP compliant production team. This commercial facility employs advanced continuous-flow cell culture technologies for high yield manufacturing (~20 g/L) as well as internally-developed cell culture media for cost-effective production. The site produces Phase III and pivotal trial clinical supplies, executes the commercial process validation, and performs the commercial manufacturing after product launch.
Genor Biopharma currently has 10+ drug candidates under development in clinical or New Drug Application (NDA) stages. Among them, the NDA for Geptanolimab (GB226) has been granted for priority review by the Center for Drug Evaluation (CDE) and has successfully passed the NDA pre-approval inspection by the National Medical Products Administration (NMPA), with a product launch targeted for 2021. It is the first PD-1 inhibitor worldwide for peripheral T-cell lymphoma (PTCL) and is expected to bring safe and high-quality therapeutic benefits to patients. The NDA filing for Infliximab (GB242) has also been accepted by CDE and is currently under review by the agency.
Beijing office
Yuxi, Yunnan - Principally Phase 3 and commercial manufacturing
Zhangjiang, Shanghai - R&D center, QC/Analytical center, cGMP sample manufacturing
South San Francisco, US - Bi-specific platform


We aspire to become a biopharmaceutical company with global presence, serving patients and society.


Our mission is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialization of innovative therapeutics initially for patients in China and gradually for patients globally.
Our History


December 2007
Genor Biopharma was incorporated in Shanghai as one of the first innovation-driven biopharmaceutical company.
November 2011
GB221(Coprelotamab)phase 1 clinical trial was successfully launched in Australia




July 2013
We obtained IND approval for GB221 in PRC
July 2014
Yuxi Genor was incorporated in Yuxi, Yunnan, PRC




January 2015
GB242 (Infliximab Biosimiliar)received IND approval from NMPA in China.
April 2016
Manufactory facility was constructed in Yuxi, Yunan




November 2016
GB226 (Geptanolimab) received IND approval from NMPA in China
April 2017
Genor Biopharma was incorporated in Cayman Islands.




December 2018
Completed Series A Financing
September 2019
Differentiated Antibody Discovery Platform, Ab Therapeutics, was established in SF, USA




May 2020
Completed Series B Financing
June 2020
In-licensed GB491 (Lerociclib, CDK4/6 inhibitor) from G1 Therapeutics;In-licensed GB492 (IMSA101, STING agonist) from ImmuneSensor Therapeutics.




July 2020
GB226 NDA submission and received priority review status
October 2020
Genor was successfully listed on HKEX (stock code 6998.HK) and raised USD$400mn




2020-2021
Further strengthened its core management team
September 2021
the first patient was dosed in the Phase 1 clinical trial of GB492(IMSA101) in China




September-October 2021
the first patient was dosed in the 1L / 2L Phase 3 clinical trial of GB491(Lerociclib) in China
October 2021
the first patient was dosed in the clinical trial of GB261(CD20/CD3) in Australia




December 2021
GB263T(EGFR/cMET/cMET) submitted a clinical trial application to the Bellberry Human Research Ethics Committee (HREC) in Australia.
2021
A number of world-renowned experts in tumor immunology & clinical oncology have been appointed as members of the Biosciences Advisory Board



February 2022
GB242 (Infliximab, biosimilar to Remicade, Jiayoujian佳佑健®) received NDA approval in the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and Pediatric Crohn’s Disease and Fistulising Crohn’s Disease.